Development of a novel chemokine signaling-based multigene signature to predict prognosis and therapeutic response in colorectal cancer  

作　　者：Xin QI Donghui YAN Jiachen ZUO Rui WANG Jiajia CHEN 

机构地区：[1]School of Chemistry and Life Sciences,Suzhou University of Science and Technology,Suzhou 215011,China

出　　处：《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》2021年第12期1053-1059,共7页浙江大学学报（英文版）B辑（生物医学与生物技术）

基　　金：supported by the National Natural Science Foundation of China(Nos.31900490 and 31770903);the Natural Science Foundation of the Jiangsu Higher Education Institutions of China(No.19KJB180027)。

摘　　要：Colorectal cancer(CRC)is the most lethal gastrointestinal cancer in both males and females worldwide(Sung et al.,2021).Because of the high heterogeneity of tumors,robust prognostic biomarkers are urgently needed in CRC management(Koncina et al.,2020).Chemokine signaling is a well-known pivotal player in immunity,inflammation,and cancer metastasis(Lacalle et al.,2017;Poeta et al.,2019;Do et al.,2020),and multiple genes involved in chemokine signaling have been demonstrated as potential prognostic biomarkers for CRC(Cabrero-De Las Heras and Martinez-Balibrea,2018;Ottaiano et al.,2020;Yu et al.,2020).Therefore,the aim of our study was to develop a chemokine signaling-based multigene signature(CSbMgSig)that could effectively predict overall survival(OS)and therapeutic response for patients with CRC.

关 键 词：THERAPEUTIC cancer 

分 类 号：R735.34[医药卫生—肿瘤]